Cardinal Health, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cardinal Health, Inc.
Aldeyra’s bid to rely on a single Phase III trial after an initial one failed is rejected by FDA, but firm already has a special protocol assessment under review for a trial that could provide the symptom data it says agency needs to approve the RASP modulator in dry eye.
Aldeyra already has a special protocol assessment under review at the FDA for a trial to provide the symptom data the agency said is needed for approval of the RASP modulator in dry eye disease.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Durect thinks its epigenetic modulator shows promise with data showing reduction in 90-day mortality despite missing the primary endpoint of mortality and liver transplant rate.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Home Infusion
- Hospitals, Nursing Homes, Institutions
- Pharmacy Services, PBMs
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Allegiance Healthcare Corporation
- Cordis Corporation
- Innovative Therapies, naviHealth
- The Harvard Drug Group
- VIASYS Healthcare
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.